Sub Banner Image

Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?

Equities

Zacks Investment Research, Inc.

·

July 18, 2025

·

Barchart

OptimizeRx OPRX delivered an encouraging first-quarter 2025, with revenues rising 11% year over year to $21.9 million and adjusted EBITDA reaching $1.5 million — a significant year-over-year turnaround. Despite its seasonally weakest quarter, OPRX is seeing momentum in its core platform, anchored by DAAP and advanced micro-neighborhood targeting. The company’s...

More from

Barchart

More

Equities

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.